Samsung Biologics moves up plans to open its $1.5B+ plant
Samsung Biologics, the contract manufacturing arm of the South Korean-based conglomerate Samsung, plans to open the doors to one of its factories a little sooner than expected.
On Tuesday, Samsung Biologics announced that it plans to have its fifth manufacturing plant operational at its Songdo site in South Korea by April 2025. The plant, into which Samsung Biologics is investing more than KRW 1.8 trillion (about $1.5 billion), is slated to break ground later this year. The facility will be 96,000 square meters, or around 1 million square feet.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.